NCT05939700Recruiting
Mavacamten Pregnancy Surveillance Program
Source: ClinicalTrials.gov · Last updated 6 Nov 2025
Brief summary (registry, in English)
The purpose of this observational pregnancy safety study is to assess maternal, fetal, and infant outcomes after exposure to mavacamten at any time during pregnancy and/or breastfeeding.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 3 Jul 2023
- Start date
- 9 Nov 2023
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Hypertrophic cardiomyopathy
- NCT number
- NCT05939700
What you commit to
- Study type: Observational
- Planned participants: 20
- From 9 Nov 2023 to the primary completion date, 30 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- None
Who the study is looking for
- Exposure to at least 1 dose of mavacamten at any time during pregnancy (from 4 months prior to conception to pregnancy outcome) and/or at any time during breastfeeding (up to 12 months of infant age or weaning, whichever comes first)
- At least 15 years of age or older at the time of enrollment
- Informed consent or institutional review board/ethics committee-approved waiver of informed consent
Age in the registry: 15 years to - · Sex: Female
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Mavacamten Pregnancy Surveillance Program, PPD Inc Coordinator of this site? Confirm its status | Wilmington | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.